Drug intelligence / Profile preview

DITEST

Development stage: Phase 1
Lead developer: Neurocrine Biosciences
Modality: Small Molecules
Administration: Oral

Overview

DITEST is an oral, lipid formulation of native testosterone developed for the treatment of androgen deficiency in men, specifically those with primary or secondary hypogonadism. It is designed to restore testosterone levels in the body, addressing the symptoms associated with low androgen levels. The drug has undergone a Phase 1 clinical study to evaluate its pharmacokinetic characteristics, safety, and tolerability in the target patient population.

Targets

AR (Adrenergic receptors)

Beyond the preview

Go deeper on DITEST.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DITEST.

Explore the full profile